Corrigendum to "Rationale and design of the NAGOYA HEART Study: Comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance", [J. Cardiol., 56, (2010), 111-117], doi:10.1016/j.jjcc.2010.03.004;Rationale and design of the NAGOYA HEART Study: Comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance

Journal of Cardiology

Volumn 56, Issue 1, 2010, Pages 111-117

  Matsushita, Kunihiro ^a   Muramatsu, Takashi ^a   Kondo, Takahisa ^a   Maeda, Kengo ^a   Shintani, Satoshi ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Cardiovascular mortality and morbidity; Diabetes mellitus; Hypertension; Impaired glucose tolerance

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DRUG DOSE INCREASE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FOLLOW UP; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; JAPANESE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE PAYMENT; RANDOMIZED CONTROLLED TRIAL; STROKE; SUDDEN DEATH;

EID: 77955552258     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.01.001     Document Type: Erratum

References (35)

1. American Diabetes Association Hypertension management in adults with diabetes. Diab Care 2004, 27:S65-S67.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289:2560-71.
3. Guidelines Committee European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
4. Vijan S., Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003, 138:593-602.
5. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998, 338:645-652.
6. Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomanmäki K., Dahlöf B., de Faire U., Mörlin C., Karlberg B.E., Wester P.O., Björck J.E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
7. Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
8. Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G., Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diab Care 1998, 21:597-603.
9. Berl T., Hunsicker L.G., Lewis J.B., Pfeffer M.A., Porush J.G., Rouleau J.L., Drury P.L., Esmatjes E., Hricik D., Parikh C.R., Raz I., Vanhille P., Wiegmann T.B., Wolfe B.M., Locatelli F., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 2003, 138:542-549.
10. Lindholm L.H., Hansson L., Ekbom T., Dahlöf B., Lanke J., Linjer E., Scherstén B., Wester P.O., Hedner T., de Faire U. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000, 18:1671-1675.
11. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713-720. U.K. Prospective Diabetes Study Group.
12. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
13. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002, 22:1257-1266.
14. Akashiba A., Ono H., Ono Y., Ishimitsu T., Matsuoka H. Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-beta inhibition and apoptosis induction in spontaneously hypertensive rats. J Cardiol 2008, 52:239-246.
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981-97.
16. Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb 2007, 14:278-286.
17. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2007 chart book on cardiovascular, lung, and blood diseases. Available at: [accessed May 7, 2009]. http://www.nhlbi.nih.gov/resources/docs/07-chtbk.pdf.
18. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialists' Collaboration.
19. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419. Blood Pressure Lowering Treatment Trialists' Collaboration.
20. Hansson L., Hedner T., Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992, 1:113-119.
21. American Diabetes Association Standards of medical care in diabetes. Diab Care 2004, 27:S15-35.
22. Tominaga M., Eguchi H., Manaka H., Igarashi K., Kato T., Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diab Care 1999, 22:920-924.
23. Japan Diabetes Society, editors. Treatment guide for diabetes 2007. Tokyo: Nankodo; 2007.
24. Fujishima M., Kiyohara Y., Kato I., Ohmura T., Iwamoto H., Nakayama K., Ohmori S., Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 1996, 45 Suppl 3:S14-S16.
25. Sone H., Mizuno S., Ohashi Y., Saito Y., Ito H., Yamasaki Y., Ohmori S., Yoshitake T. Current situation of macrovascular complication in Japanese patients with type 2 diabetes mellitus-interim results of the Japan Diabetes Complications Study (JDCS). Diab Front 2003, 14:588-592. (in Japanese).
26. Whelton P.K., Barzilay J., Cushman W.C., Davis B.R., Iiamathi E., Kostis J.B., Leenen F.H., Louis G.T., Margolis K.L., Mathis D.E., Moloo J., Nwachuku C., Panebianco D., Parish D.C., Pressel S., et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401-1409.
27. Yui Y., Sumiyoshi T., Kodama K., Hirayama A., Nonogi H., Kanmatsuse K., Origasa H., Iimura O., Ishii M., Saruta T., Arakawa K., Hosoda S., Kawai C. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004, 27:181-191. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group.
28. Casas J.P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A.D., MacAllister R.J. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366:2026-2033.
29. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031. VALUE Trial Group.
30. Ogihara T., Nakao K., Fukui T., Fukiyama K., Ueshima K., Oba K., Sato T., Saruta T. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008, 51:393-398. Candesartan Antihypertensive Survival Evaluation in Japan Trial Group.
31. Ogihara T., Fujimoto A., Nakao K., Saruta T. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Expert Rev Cardiovasc Ther 2008, 6:1195-1201.
32. Mochizuki S., Dahlöf B., Shimizu M., Ikewaki K., Yoshikawa M., Taniguchi I., Ohta M., Yamada T., Ogawa K., Kanae K., Kawai M., Seki S., Okazaki F., Taniguchi M., Yoshida S., et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007, 369:1431-1439.
33. Sawada T., Yamada H., Dahlöf B., Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009, 30:2461-2469. KYOTO HEART Study Group.
34. Messerli F.H., Bangalore S., Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension?. Eur Heart J 2009, 30:2427-2430.
35. Strauss M.H., Hall A.S. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009, 31:261-262.